Case study · Dermocosmetics
How do Chinese dermatologists actually recommend?
Ninety dermatologist interviews across ten cities, and a sequence that explains why scientific credibility was not converting into recommendations.
What they asked
A European active-cosmetic brand with high scientific standing in China wanted to understand how dermatologists form and give recommendations in dermocosmetics — where its influence levers were, where localised competitors had taken ground, and what its hospital strategy should be.
What we did
- Strategic qualitative research: 90 dermatologist interviews
- Medical–cosmetic crossover regulation and hospital access pathways
- Competitive analysis of other dermocosmetic brands
- Digital footprint and academic engagement audit
How it ran
Design the sample around the decision
Sixty interviews in tier-one cities and thirty in tier-two and lower, face-to-face and on WeChat, with dermatologists from Class III hospitals across a spread of seniority. Four focus areas: sampling behaviour, academic visibility, digital learning, and the public-hospital entry route.
Find the trust mechanism
The finding was consistent and inconvenient: doctors must use a product before they recommend it, and access to samples inside public hospitals is limited. The sample is not a promotional item in this category — it is the trust mechanism.
Read the competitor correctly
Local brands were not winning on media weight. They were winning through professor-endorsed consensus papers and visible hospital presence — an academic strategy, run patiently.
Watch how doctors actually learn
Medical visits work when they are short, data-driven and sample-supported; cold calls do not. Continuing education runs through professional platforms and WeChat, and what earns attention there is clinical data, not lifestyle content.
Outcome
- A documented recommendation pathway: clinical collaboration → doctor experience → patient trial → recommendation.
- A clear read of where scientific credibility was failing to convert, and why.
- A hospital engagement strategy built on sample accessibility and data-based digital education.
- A competitive picture that named the mechanism, not just the market share.
What it taught us
A brand can hold the highest scientific credibility in its category and still lose ground, if the people who convert that credibility into a recommendation have never used the product.
Other engagements
A distribution network built one relationship at a time
Twenty-plus qualified distribution partners, KOL endorsement and a working demo-to-installation chain for a dialysis data technology entering China.
Read the case → Diagnostics · oncology biomarkerFinding the fastest legitimate route for a cancer-screening biomarker
A fast-track regulatory plan for the hPg80 biomarker, a Taiwan-first sequence, and clinical collaboration with Chinese oncologists.
Read the case → Medical device · endovascular softwareSix years running the China business of a French SME
A market that was not ready, a partnership with a stentgraft manufacturer, and a distribution network we have managed on the client’s behalf since.
Read the case →